Department of Medicine, Division of Allergy and Clinical Immunology, Baltimore, Md., USA.
Respiration. 2013;86(3):243-51. doi: 10.1159/000350451. Epub 2013 Jul 16.
Deep inspirations (DIs) can prevent (bronchoprotection; BP) and reverse (bronchodilation; BD) methacholine (Mch)-induced bronchoconstriction, but this effect is reduced or absent in people with asthma or airways hyperresponsiveness (AHR). The mechanisms of this defect are unknown.
To indirectly examine the role of guanosine 3',5'-cyclic monophosphate (cGMP) by testing the hypothesis that the phosphodiesterase (PDE) V inhibitor, sildenafil, would improve DI-induced BP in individuals with AHR.
Thirty-two individuals were screened and 15 met all the inclusion/exclusion criteria (7 subjects with AHR and 8 healthy subjects). A single-dose Mch challenge inducing a 20% reduction in FEV1 in the absence of DIs was first identified. Thereafter, every study participant had 4 pairs of visits, each pair testing DI-induced BP and BD against the single-dose Mch, with no drug, or pretreatment with 25, 50 and 100 mg of sildenafil, respectively, in consecutive order.
Sildenafil did not influence baseline lung function. However, in the absence of DIs, the drug caused a dose-dependent attenuation of the Mch-induced decrease in FEV1 by 17% (median value; 25th percentile: 1, 75th percentile: 16), 35% (-3, 61) and 37% (13, 79) for the 25-, 50- and 100-mg doses, respectively (p = 0.0004). No differences between the two participant groups were found. There were no effects of sildenafil on DI-induced BP or BD.
We infer from these results that the mechanism responsible for the defective ability of DIs to protect the airways from bronchoconstriction is unlikely to be due to dysregulation of cGMP. Of importance, a potential role for PDE V inhibition as a bronchoprotector treatment needs to be explored.
深吸气(DIs)可以预防(支气管保护;BP)和逆转(支气管扩张;BD)乙酰甲胆碱(Mch)引起的支气管收缩,但在哮喘或气道高反应性(AHR)患者中,这种作用会降低或消失。这种缺陷的机制尚不清楚。
通过测试磷酸二酯酶(PDE)V 抑制剂西地那非是否会改善 AHR 个体的 DIs 诱导的 BP,间接检验环鸟苷酸(cGMP)的作用。
筛选了 32 名个体,其中 15 名符合所有纳入/排除标准(7 名 AHR 患者和 8 名健康受试者)。首先确定了无 DIs 时单次 Mch 激发导致 FEV1 降低 20%的剂量。此后,每位研究参与者进行了 4 对检查,每对检查 DIs 诱导的 BP 和 BD 与单次 Mch 的关系,分别在无药物、或分别用 25、50 和 100mg 西地那非预处理的情况下进行,连续进行。
西地那非不影响基础肺功能。然而,在没有 DIs 的情况下,药物剂量依赖性地减弱了 Mch 引起的 FEV1 下降,25mg 剂量下降 17%(中位数;25%分位数:1,75%分位数:16),50mg 剂量下降 35%(-3,61),100mg 剂量下降 37%(13,79)(p=0.0004)。在两组参与者之间未发现差异。西地那非对 DIs 诱导的 BP 或 BD 没有影响。
从这些结果推断,DIs 保护气道免受支气管收缩的能力缺陷的机制不太可能是由于 cGMP 调节失调。重要的是,需要探索 PDE V 抑制作为支气管保护治疗的潜在作用。